INVO Bioscience, Inc. (OTC Bulletin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOLFES LTDA) in Bogota, Colombia presented the results of the Center's first 95 fertility treatment cycles utilizing INVO Bioscience's INVOcell for couples with fertility issues at the 66th Annual Meeting of the American Society of Reproductive Medicine (ASRM) in Denver.
The presentation revealed that CECOLFES produced clinical pregnancy rates of 43% per INVOcell cycle and a 48% clinical pregnancy rate when an embryo has been transferred in the cycle. This outstanding effectiveness was achieved in cycles completed in women from ages 21 to 45. The clinical pregnancy rate for patients aged 40 and younger was 46%. According to the U.S. Center for Disease Control (CDC) current infertility treatments are in the same range of efficacy. The CECOLFES results also indicated that multiple pregnancies occurred in 10% of the patients in the study compared to 30% multiple pregnancies that occur in more traditional fertility treatment regimes. Multiple pregnancies can cause very serious and expensive complications.
Claude Ranoux, MD, MS, president and chief scientific officer for INVO Bioscience, Inc., commented, "We are delighted with the results presented by the Colombian Fertility and Sterility Center and Dr. Lucena. These results are consistent with our in-house data. It is important to note that in the INVOcell process significantly fewer eggs are recruited from patients, which decreases the risk of multiple births and reduces the number of premature births. Combining the comparative cost advantage of the INVOcell treatment versus current treatment regimes, and the ability to significantly reduce the occurrence of multiple pregnancies and their substantial incremental costs, positions INVOcell as an important therapy for infertility patients. The INVO procedure can generate outstanding results while significantly bringing down fertility treatment costs. We are very pleased with these results."
Dr. Ranoux continued, "The report of these results is an important development in the history of the INVOcell device and process. The presentation of the positive results of this data at the prestigious ASRM Annual Meeting represents a powerful affirmation by one of the renowned pioneers in the fertility field, Dr. Lucena, as an effective, safe, and cost efficient technology. The INVO procedure will address a problem that affects millions of infertile patients worldwide. We look forward to leveraging this event as we continue our efforts to widely commercialize this revolutionary alternative for deserving patients in need of these life-fulfilling treatments."
INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Canada, Cameroon, Columbia, Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, and Venezuela.
COVID-19 reduces male fertility by affecting semen quality and hormone levels